Nerve growth factor affects11C-nicotine binding, blood
memory in an Alzheimer patient (Case Report)

Journal of Neural Transmission Parkinson's Disease and Demer

4, 79-95

DOI: 10.1007/bf02257624

Citation Report

#	Article	IF	Citations
1	Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. Journal of Neuroscience, 1992, 12, 4391-4402.	3.6	280
2	(S)- and (R)-[11C]nicotine and the metabolite ()-[11C]cotinine. preparation, metabolite studies and in vivo distribution in the human brain using PET. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1992, 19, 871-880.	0.3	44
3	Pharmacological stimulation reveals recombinant human nerve growth factor-induced increases of in vivo hippocampal cholinergic function measured in rats with partial fimbrial transections. Neuroscience, 1992, 50, 847-856.	2.3	23
4	Tacrine restores cholinergic nicotinic receptors and glucose metabolism in alzheimer patients as visualized by positron emission tomography. Neurobiology of Aging, 1992, 13, 747-758.	3.1	145
5	The pharmacological potential of neurotrophins: A perspective. Psychoneuroendocrinology, 1992, 17, 401-410.	2.7	18
6	Two-site enzyme immunoassay for Î²NGF applied to human patient sera. Journal of Neuroscience Research, 1992, 32, 329-339.	2.9	31
7	Function and evolution in the NGF family and its receptors. Journal of Neuroscience Research, 1992, 32, 461-470.	2.9	332
8	Neurotrophic factor mediated protection from excitotoxicity and disturbances in calcium and free radical metabolism. Seminars in Neuroscience, 1993, 5, 295-307.	2.2	50
9	Localisation of muscarinic (m1) and other neurotransmitter receptors on corticofugal-projecting pyramidal neurones. Brain Research, 1993, 632, 86-94.	2.2	35
10	Effects of oral administration of a stimulator for nerve growth factor synthesis in basal forebrain-lesioned rats. European Journal of Pharmacology, 1993, 250, 23-30.	3.5	21
11	Clinical studies in Alzheimer patients with positron emission tomography. Behavioural Brain Research, 1993, 57, 215-224.	2.2	67
12	Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy. Behavioural Brain Research, 1993, 57, 255-261.	2.2	145
13	Overview of Age-Related Dementias. Drug Investigation, 1993, 5, 1-3.	0.6	0
14	Regulation of hippocampal muscarinic receptor function by chronic nerve growth factor treatment in adult rats with fimbrial transections. Neuroscience, 1993, 53, 379-394.	2.3	21
15	Regulation of the transcription factor c-JUN by nerve growth factor in adult sensory neurons. Neuroscience Letters, 1993, 154, 129-133.	2.1	72
16	CNS glial cells express neurotrophin receptors whose levels are regulated by NGF. Molecular Brain Research, 1993, 17, 163-168.	2.3	67
17	Distribution of [125I]nerve growth factor in the rat brain following a single intraventricular injection: Correlation with the topographical distribution of trk a messenger RNA-expressing cells. Neuroscience, 1993, 54, 445-460.	2.3	67
18	Oral administration of idebenone, a stimulator of NGF synthesis, recovers reduced NGF content in aged rat brain. Neuroscience Letters, 1993, 163, 219-222.	2.1	42

#	Article	IF	Citations
19	Altered Calcium Signaling and Neuronal Injury: Stroke and Alzheimer's Disease as Examples. Annals of the New York Academy of Sciences, 1993, 679, 1-21.	3.8	109
20	In Vivo Detection of Neurotransmitter Changes in Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1993, 695, 27-33.	3.8	30
21	Drug treatment of cognitive impairment and emotional disturbances in the elderly. Nordic Journal of Psychiatry, 1993, 47, 59-65.	1.3	2
22	Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science, 1993, 259, 373-377.	12.6	308
23	Pharmacology of Nerve Growth Factor in the Brain. Advances in Pharmacology, 1993, 24, 239-273.	2.0	19
24	Cellular and molecular pathology in alzheimer's disease. Hippocampus, 1993, 3, 270-287.	1.9	48
25	Roles for calcium signaling in structural plasticity and pathology in the hippocampal system. Hippocampus, 1993, 3, 73-87.	1.9	33
26	Sustained Intracerebral Delivery of Nerve Growth Factor with Biodegradable Polymer Microspheres. Methods in Neurosciences, 1994, 21, 150-168.	0.5	16
27	Pharmacotherapy for Alzheimerâ€™s Disease. Clinics in Geriatric Medicine, 1994, 10, 339-350.	2.6	7
28	Effects of Nerve Growth Factor in Primate Models of Neurodegeneration: Potential Relevance in Clinical Neurology. Reviews in the Neurosciences, 1994, 5, 89-104.	2.9	9
29	Growth factors: potential therapeutic applications in neurology.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1445-1450.	1.9	16
30	PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo. Psychopharmacology, 1994, 115, 31-36.	3.1	101
31	Effect of nerve growth factor and GM1 ganglioside on the recovery of cholinergic neurons after a lesion of the nucleus basalis in aging rats. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1994, 7, 177-193.	1.2	18
32	Pyritinol facilitates the recovery of cortical cholinergic deficits caused by nucleus basalis lesions. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1994, 7, 195-209.	1.2	14
33	Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. Journal of Neurology, 1994, 242, S12-S15.	3.6	44
34	Neurotrophic factor therapy for nervous system degenerative diseases. Journal of Neurobiology, 1994, 25, 1418-1435.	3.6	257
35	The role of growth factors and neuropeptides in alzheimer's disease. Human Psychopharmacology, 1994, 9, 353-356.	1.5	0
36	NGF increases neuritic complexity of cholinergic interneurons in organotypic cultures of neonatal rat striatum. Journal of Comparative Neurology, 1994, 340, 281-296.	1.6	35

#	Article	IF	Citations
37	Highly selective effects of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 on intact and injured basal forebrain magnocellular neurons. Journal of Comparative Neurology, 1994, 343, 247-262.	1.6	112
38	Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: Rescue and sprouting of degenerating cholinergic basal forebrain neurons. Journal of Comparative Neurology, 1994, 349, 148-164.	1.6	196
39	Nerve growth factor and other neurotrophins in Alzheimer's disease. International Journal of Geriatric Psychiatry, 1994, 9, 861-869.	2.7	0
40	Review: Tissue engineering in the nervous system. Biotechnology and Bioengineering, 1994, 43, 543-554.	3.3	72
41	Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basal forebrain-lesioned rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1994, 349, 401-407.	3.0	37
42	Effect of epidermal growth factor, transforming growth factor Î± and nerve growth factor on gastric mucosal integrity and microcirculation in the rat. Regulatory Peptides, 1994, 50, 13-21.	1.9	33
43	Development of effective therapy for Alzheimer's disease based on neurotrophic factors. Neurobiology of Aging, 1994, 15, 193-194.	3.1	27
44	Chronic 1,25-dihydroxyvitamin D3-mediated induction of nerve growth factor mRNA and protein in L929 fibroblasts and in adult rat brain. Brain Research, 1994, 633, 189-196.	2.2	79
45	Neurotrophic factors in memory disorders. Life Sciences, 1994, 55, 2165-2169.	4.3	23
46	Memory disorders: Novel treatments, clinical perspective. Life Sciences, 1994, 55, 2189-2194.	4.3	10
47	Human nicotinic receptorsâ€"Their role in aging and dementia. Neurochemistry International, 1994, 25, 93-97.	3.8	109
48	Neurotrophins in neurodegenerative disease: Theoretical issues and clinical trials. Neurochemistry International, 1994, 25, 1-3.	3.8	11
49	Nerve growth factor increases extracellular acetylcholine levels in the parietal cortex and hippocampus of aged rats and restores object recognition. Neuroscience Letters, 1994, 170, 117-120.	2.1	82
50	Effects of chronic nerve growth factor treatment on hippocampal [3H]cytisine/ nicotinic binding sites and presynaptic nicotinic receptor function following fimbrial transections. Neuroscience, 1994, 60, 293-298.	2.3	11
51	Neuropathobiology of Senile Dementia and Mechanism of Action of Nootropic Drugs. Drugs and Aging, 1994, 4, 285-303.	2.7	16
52	Clinical Potential of Growth Factors in Neurological Disorders. CNS Drugs, 1994, 2, 465-478.	5.9	7
53	An Investigation of Antibodies to Nerve Growth Factor in Diabetic Autonomic Neuropathy. Diabetic Medicine, 1994, 11, 378-383.	2.3	20
54	Nerve Growth Factor Content of Rat Brain Increases Following Basal-Forebrain Lesions Induced by Ibotenic Acid but Not by Electrolysis.. Biological and Pharmaceutical Bulletin, 1994, 17, 34-38.	1.4	5

#	Article	IF	Citations
55	Chapter 9 The central cholinergic system during aging. Progress in Brain Research, 1994, 100, 67-71.	1.4	62
56	Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9077-9080.	7.1	115
57	The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 10898-10902.	7.1	191
58	Effects of Brain-derived Neurotrophic Factor on 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in Monkeys. Neurosurgery, 1995, 37, 733-741.	1.1	134
59	The effect of glial cell line-derived neurotrophic factor in fibrin glue on developing dopamine neurons. Experimental Brain Research, 1995, 104, 199-206.	1.5	36
60	Radical directions in Parkinson's disease. Nature Medicine, 1995, 1, 201-203.	30.7	9
61	The regulation of nerve growth factor synthesis and delivery to peripheral neurons. , 1995, 65, 93-123.		27
62	Cholinergic neurotransmission studied in vivo using positron emission tomography or single photon emission computerized tomography. , 1995, 66, 83-101.		39
63	Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. Journal of Neuroscience, 1995, 15, 6213-6221.	3.6	270
64	The treatment of Alzheimer's disease. Journal of Psychopharmacology, 1995, 9, 43-56.	4.0	24
65	Effects of transferrin receptor antibodyâ€"NGF conjugate on young and aged septal transplants in oculo. Experimental Neurology, 1995, 132, 1-15.	4.1	29
66	Facilitation of learning following injection of the chondroitin sulfate proteoglycan biglycan into the vicinity of the nucleus basalis magnocellularis. Behavioural Brain Research, 1995, 70, 59-67.	2.2	20
67	Effects of intraventricular encapsulated hNGF-secreting fibroblasts in aged rats. Cell Transplantation, 1996, 5, 205-223.	2.5	53
68	Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience, 1996, 75, 373-387.	2.3	139
69	Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?. Trends in Pharmacological Sciences, 1996, 17, 155-160.	8.7	47
70	Neurotrophins and Alzheimer's disease: Beyond the cholinergic neurons. Life Sciences, 1996, 58, 2019-2027.	4.3	37
71	Propentofylline prevents neuronal dysfunction induced by infusion of anti-nerve growth factor antibody into the rat septum. European Journal of Pharmacology, 1996, 307, 1-6.	3.5	15
72	Treatment of Alzheimer's disease: future directions. Acta Neurologica Scandinavica, 1996, 94, 128-136.	2.1	7

#	Article	IF	Citations
73	Functional studies of new drugs for the treatment of Alzheimer's disease. Acta Neurologica Scandinavica, 1996, 94, 137-144.	2.1	15
74	Emotions and the Aging Brain. , 1996, , 3-26.		34
76	Systemic Administration of a Nerve Growth Factor Conjugate Reverses Age-Related Cognitive Dysfunction and Prevents Cholinergic Neuron Atrophy. Journal of Neuroscience, 1996, 16, 5437-5442.	3.6	139
77	Synthesis and evaluation of a brain-targeted catechol derivative as a potential NGF-inducer. International Journal of Pharmaceutics, 1996, 141, 239-250.	5.2	13
78	Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Cell and Tissue Research, 1996, 286, 179-189.	2.9	53
79	Dementia: diagnostics, early treatment, and assistance from family members. Acta Neurologica Scandinavica, 1996, 94, 2-22.	2.1	5
80	Pharmacological treatment of cognitive dysfunction in dementia disorders. Acta Neurologica Scandinavica, 1996, 94, 87-92.	2.1	29
81	Episodic memory deficit in elderly adults with suspected delusional disorder. Acta Psychiatrica Scandinavica, 1996, 93, 355-361.	4.5	16
82	Chronic Infusion of Nerve Growth Factor into Rat Striatum Increases Cholinergic Markers and Inhibits Striatal Neuronal Discharge Rate. European Journal of Neuroscience, 1996, 8, 1822-1832.	2.6	21
83	Regulation of Nerve Growth Factor mRNA by Interleukin-1 in Rat Hippocampal Astrocytes Is Mediated by NFÎºB. Journal of Biological Chemistry, 1996, 271, 31115-31120.	3.4	91
84	Human Melanocytes as a Model System for Studies of Alzheimer Disease. Archives of Dermatology, 1997, 133, 1287.	1.4	15
85	PHARMACOLOGY OF NEUROTROPHIC FACTORS. Annual Review of Pharmacology and Toxicology, 1997, 37, 239-267.	9.4	175
86	Cellular Delivery of NGF Does Not Alter the Expression of Î²-Amyloid Immunoreactivity in Young or Aged Nonhuman Primates. Experimental Neurology, 1997, 145, 586-591.	4.1	28
87	Selective Loss of Cholinergic Receptors Following Unilateral Intracortical Injection of Volkensin. Experimental Neurology, 1997, 147, 183-191.	4.1	6
88	The Use of Nonneuronal Cells for Gene Delivery. Neurobiology of Disease, 1997, 4, 69-102.	4.4	52
89	Orally active NGF synthesis stimulators: potential therapeutic agents in alzheimer's disease. Behavioural Brain Research, 1997, 83, 117-122.	2.2	49
90	Oral administration of propentofylline, a stimulator of nerve growth factor (NGF) synthesis, recovers cholinergic neuronal dysfunction induced by the infusion of anti-NGF antibody into the rat septum. Behavioural Brain Research, 1997, 83, 201-204.	2.2	18
91	The cholinergic system in Alzheimer's disease. Progress in Neurobiology, 1997, 52, 511-535.	5.7	362

#	Article	IF	Citations
92	Drugs for the prevention and treatment of Alzheimer's disease. Medical Journal of Australia, 1997, 167, 447-452.	1.7	9
93	Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor. Nature Biotechnology, 1997, 15, 668-672.	17.5	51
94	Regeneration in the adult central nervous system: Experimental repair strategies. Nature Medicine, 1997, 3, 1329-1335.	30.7	103
95	Enhancing Cognition in the Intellectually Intact. Hastings Center Report, 1997, 27, 14.	1.0	60
96	Changes in cortical EEG and cholinergic function in response to NGF in rats with nucleus basalis lesions. Brain Research, 1997, 765, 228-237.	2.2	17
97	The novel compound TDN-345 induces synthesis/secretion of nerve growth factor in C6-10A glioma cells. Brain Research, 1997, 774, 87-93.	2.2	6
98	Utilization of an endogenous cellular transport system for the delivery of therapeutics across the bloodâ€“brain barrier. Journal of Controlled Release, 1997, 46, 117-128.	9.9	10
99	Intraventricular injection of NGF, but not BDNF, induces rapid motor activation that is inhibited by nicotinic receptor antagonists. Experimental Brain Research, 1997, 116, 315-325.	1.5	17
100	Reversible schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Annals of Neurology, 1997, 41, 82-93.	5.3	133
101	Bifunctional fusion between nerve growth factor and a transferrin receptor antibody. , 1997, 47, 123-133.		21
102	Experimental and clinical methods in the development of antiâ€Alzheimer drugs. Fundamental and Clinical Pharmacology, 1998, 12, 13-29.	1.9	14
103	Cholecystokinin-8 regulation of NGF concentrations in adult mouse brain through a mechanism involving CCKA and CCKB receptors. British Journal of Pharmacology, 1998, 123, 1230-1236.	5.4	25
104	Growth factor therapy. Mental Retardation and Developmental Disabilities Research Reviews, 1998, 4, 212-222.	3.6	12
105	The time course of nerve growth factor content in different neuropsychiatric diseases - a unifying hypothesis. Journal of Neural Transmission, 1998, 105, 871-903.	2.8	60
106	Tryptophan and its metabolite, kynurenine, stimulate expression of nerve growth factor in cultured mouse astroglial cells. Neuroscience Letters, 1998, 244, 17-20.	2.1	28
107	Propentofylline improves learning and memory deficits in rats induced by Î²-amyloid protein-(1-40). European Journal of Pharmacology, 1998, 349, 15-22.	3.5	57
108	A Non-invasive System for Delivering Neural Growth Factors across the Blood-Brain Barrier: A Review. Reviews in the Neurosciences, 1998, 9, 31-55.	2.9	63
109	Memory Changes during Normal Aging. , 1998, , 247-287.		10

#	Article	IF	Citations
110	Chapter 8 Neurotrophin receptors in Alzheimer's disease. Progress in Brain Research, 1998, 117, 71-89.	1.4	8
111	Chapter 32 Neurotrophin gene therapy in CNS models of trauma and degeneration. Progress in Brain Research, 1998, 117, 473-484.	1.4	51
112	Experimental Approaches to Cognitive Disturbance in Alzheimer's Disease. Harvard Review of Psychiatry, 1998, 6, 11-22.	2.1	15
113	Advances in Methodology and Current Prospects for Primary Drug Therapies for Alzheimer's Disease. , 2000, 32, 45-62.		1
114	Intraventricular infusion of nerve growth factor as the cause of sympathetic fiber sprouting in sensory ganglia. Journal of Neurosurgery, 1999, 91, 447-453.	1.6	32
115	Clinical Neurophysiology Using Electroencephalography in Geriatric Psychiatry: Neurobiologic Implications and Clinical Utility. Journal of Geriatric Psychiatry and Neurology, 1999, 12, 150-164.	2.3	15
116	Decrease in the Levels of NGF and BDNF in Brains of Mice Fed a Tryptophan-Deficient Diet. Bioscience, Biotechnology and Biochemistry, 1999, 63, 337-340.	1.3	16
117	Cholecystokinin-8 protects central cholinergic neurons against fimbria-fornix lesion through the up-regulation of nerve growth factor synthesis. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 6473-6477.	7.1	33
118	Acute application of NGF increases the firing rate of aged rat basal forebrain neurons. European Journal of Neuroscience, 1999, 11, 2291-2304.	2.6	29
119	GDNF. Molecular Neurobiology, 1999, 19, 43-59.	4.0	27
120	Behavioral effects of neurotrophic factor supplementation in aging. Age, 1999, 22, 1-7.	3.0	2
121	A commentary on glial cell line-derived neurotrophic factor (GDNF). Biochemical Pharmacology, 1999, 57, 135-142.	4.4	61
122	Drug development for neurodegenerative diseases: role of PET. Annals of Medicine, 1999, 31, 444-449.	3.8	3
123	In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11C]MPA compared with [11C]ABT-418 and (S)(â^')[11C]nicotine in Rhesus monkeys. Nuclear Medicine and Biology, 1999, 26, 633-640.	0.6	30
124	Neurotrophic Factor Strategies for the Treatment of Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2000, 14, S39-S46.	1.3	9
125	The Hippocampus: Anatomy, Pathophysiology, and Regenerative Capacity. Journal of Head Trauma Rehabilitation, 2000, 15, 875-894.	1.7	28
126	Nerve Growth Factor Treatment in Dementia. Alzheimer Disease and Associated Disorders, 2000, 14, S31-S38.	1.3	50
127	Alzheimer Disease: Current Therapy and Future Therapeutic Strategies. Alzheimer Disease and Associated Disorders, 2000, 14, S11-S17.	1.3	9

#	Article	IF	Citations
128	Termitomycesphins Aâ€“D, Novel Neuritogenic Cerebrosides from the Edible Chinese Mushroom Termitomyces albuminosus. Tetrahedron, 2000, 56, 5835-5841.	1.9	72
129	Lembehyne A, a Novel Neuritogenic Polyacetylene, from a Marine Sponge of Haliclona sp.. Tetrahedron, 2000, 56, 9945-9948.	1.9	45
130	Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurologica Scandinavica, 2000, 102, 27-33.	2.1	42
131	Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy. Journal of Neural Transmission, 2000, 107, 815-829.	2.8	67
132	Cyclohexenonic Long-Chain Fatty Alcohols as Neuronal Growth Stimulators. Molecules, 2000, 5, 1439-1460.	3.8	33
133	Clinical experience with CerebrolysinÂ®. , 2000, , 293-300.		3
134	Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimerâ€™s disease and Parkinsonâ€™s disease. Behavioural Brain Research, 2000, 113, 121-129.	2.2	77
135	Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behavioural Brain Research, 2000, 113, 143-157.	2.2	85
136	Atteindre les neurones. Biofutur, 2000, 2000, 28-31.	0.0	0
137	GABAB receptor antagonists elevate both mRNA and protein levels of the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) but not neurotrophin-3 (NT-3) in brain and spinal cord of rats. Neuropharmacology, 2000, 39, 449-462.	4.1	78
138	Neurotrophins and activity-dependent plasticity. Progress in Brain Research, 2000, 128, 183-191.	1.4	234
139	Delivery of Neurotrophic Factors to the Central Nervous System. Clinical Pharmacokinetics, 2001, 40, 907-946.	3.5	415
140	Identification and Structure of the Nerve Growth Factor Binding Site on TrkA. Biochemical and Biophysical Research Communications, 2001, 282, 131-141.	2.1	37
141	Overview and perspective on the therapy of alzheimer's disease from a preclinical viewpoint. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2001, 25, 193-209.	4.8	22
142	Recombinant human nerve growth factor for clinical trials: protein expression, purification, stability and characterisation of binding to infusion pumps. Journal of Proteomics, 2001, 47, 239-255.	2.4	19
143	Deafferentation of the septo-hippocampal pathway in rats as a model of the metabolic events in Alzheimer's disease. International Journal of Developmental Neuroscience, 2001, 19, 263-277.	1.6	35
144	Cholinergic Basal Forebrain Systems in the Primate Central Nervous System: Anatomy, Connectivity, Neurochemistry, Aging, Dementia, and Experimental Therapeutics. , 2001, , 243-281.		6
145	Purification and characterization of murine beta-nerve growth factor. Biomedical Applications, 2001, 753, 245-252.	1.7	6

#	Article	IF	Citations
146	Total synthesis of lembehyne A, a neuritogenic spongean polyacetylene. Tetrahedron Letters, 2001, 42, 1941-1943.	1.4	29
147	Neurotrophins: possible role in affective disorders. Human Psychopharmacology, 2001, 16, 61-64.	1.5	11
148	Neurotrophic activity of 2,4,4-trimethyl-3-(15-hydroxypentadecyl)-2-cyclohexen-1-one in cultured central nervous system neurons. Brain Research, 2001, 920, 65-73.	2.2	21
149	Neurotrophic Factor Therapy â€“ Prospects and Problems. Clinical Chemistry and Laboratory Medicine, 2001, 39, 351-5.	2.3	70
150	Update on Immunoisolation Cell Therapy for CNS Diseases. Cell Transplantation, 2001, 10, 3-24.	2.5	21
151	Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier. Drug Development and Industrial Pharmacy, 2002, 28, 1-13.	2.0	522
152	Dose-Dependent Neuroprotective Effect of Ciliary Neurotrophic Factor Delivered via Tetracycline-Regulated Lentiviral Vectors in the Quinolinic Acid Rat Model of Huntington's Disease. Human Gene Therapy, 2002, 13, 1981-1990.	2.7	109
153	Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurology, The, 2002, 1, 51-57.	10.2	120
154	Inhibitors of nitric oxide synthase attenuate nerve growth factor-mediated increases in choline acetyltransferase expression in PC12 cells. Journal of Neurochemistry, 2002, 81, 624-635.	3.9	21
155	Neurite outgrowth promoting activity of marine algae from Japan against rat adrenal medulla pheochromocytoma cell line, PC12D. Cytotechnology, 2002, 40, 99-106.	1.6	18
156	Correlation between neurotrophic factor expression and outcome of children with severe traumatic brain injury. Intensive Care Medicine, 2003, 29, 1329-1338.	8.2	73
157	Induction of NGF synthesis in astrocytes by onjisaponins of Polygala tenuifolia, constituents of Kampo (Japanese herbal) medicine, Ninjin-Yoei-To. Phytomedicine, 2003, 10, 106-114.	5.3	48
158	Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors. Journal of Controlled Release, 2003, 87, 107-115.	9.9	47
159	Chronic nicotine administration increases NGF-like immunoreactivity in frontoparietal cerebral cortex. Journal of Neuroscience Research, 2003, 73, 708-716.	2.9	20
160	In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Annals of Neurology, 2003, 53, S120-S134.	5.3	105
161	Neurotrophins and neurodegeneration. Neuropathology and Applied Neurobiology, 2003, 29, 211-230.	3.2	183
162	Neurotrophins. Advances in Experimental Medicine and Biology, 2003, 513, 303-334.	1.6	66
163	2 [18 F]Fâ€A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB Journal, 2003, 17, 1331-1333.	0.5	112

#	Article	IF	Citations
164	Effect of cyclohexenonic long-chain fatty alcohol on rat overactive bladder induced by bladder neck obstruction. European Journal of Pharmacology, 2004, 501, 143-149.	3.5	17
165	Neurochemical imaging of dementias. Seminars in Nuclear Medicine, 2004, 34, 70-82.	4.6	19
166	Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells. Acta Pharmacologica Sinica, 2005, 26, 673-678.	6.1	53
167	What Has Intrinsic Signal Optical Imaging Taught Us About NGF-Induced Rapid Plasticity in Adult Cortex and Its Relationship to the Cholinergic System?. Molecular Imaging and Biology, 2005, 7, 14-21.	2.6	8
168	Intraventricular nerve growth factor infusion: a possible treatment for neurological deficits following hypoxicâ€“ischemic brain injury in infants. Neurological Research, 2005, 27, 741-746.	1.3	35
169	Therapeutic Potential of Neurotrophic Factors in Neurodegenerative Diseases. BioDrugs, 2005, 19, 97-127.	4.6	71
170	The p75 neurotrophin receptor in human development and disease. Progress in Neurobiology, 2005, 77, 201-214.	5.7	90
171	Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx, 2005, 2, 120-128.	6.0	129
172	Calcium and Neuronal Injury in Alzheimer's Disease. Annals of the New York Academy of Sciences, 1994, 747, 50-76.	3.8	122
173	Nerve growth factor in treatment and pathogenesis of Alzheimer's disease. Progress in Neurobiology, 2006, 80, 114-128.	5.7	80
174	Neurotrophin gene therapy for Alzheimerâ€™s disease. Future Neurology, 2006, 1, 179-187.	0.5	6
175	Cytoskeletal Transport in the Aging Brain: Focus on the Cholinergic System. Reviews in the Neurosciences, 2006, 17, 581-618.	2.9	19
176	Neurotrophic Factors in Neurodegeneration. Brain Pathology, 2006, 16, 295-303.	4.1	49
177	Kâ€252 Compounds: Modulators of Neurotrophin Signal Transduction. Journal of Neurochemistry, 1992, 59, 1987-1996.	3.9	226
178	Gene delivery to the spinal cord: Comparison between lentiviral, adenoviral, and retroviral vector delivery systems. Journal of Neuroscience Research, 2006, 84, 553-567.	2.9	60
179	Î²/A4â€Amyloid increases nerve growth factor production in rat primary hippocampal astrocyte cultures. International Journal of Developmental Neuroscience, 2007, 25, 387-390.	1.6	8
180	NGF topical application in patients with corneal ulcer does not generate circulating NGF antibodies. Pharmacological Research, 2007, 56, 65-69.	7.1	34
181	Beta-amyloid peptide - nicotinic acetylcholine receptor interaction: the two faces of health and disease. Frontiers in Bioscience - Landmark, 2007, 12, 5030.	3.0	76

#	Article	IF	Citations
182	Imaging treatment effects in Alzheimer's disease. Magnetic Resonance Imaging, 2007, 25, 953-968.	1.8	40
183	Staurosporine, Kâ€252a, and Kâ€252b Stabilize Calcium Homeostasis and Promote Survival of CNS Neurons in the Absence of Glucose. Journal of Neurochemistry, 1994, 62, 1319-1329.	3.9	35
184	Nerve growth factor expression correlates with severity and outcome of traumatic brain injury in children. European Journal of Paediatric Neurology, 2008, 12, 195-204.	1.6	60
185	Therapeutic potential of CERE-110 (AAV2-NGF): Targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Experimental Neurology, 2008, 211, 574-584.	4.1	76
186	Interleukin-6 and Nerve Growth Factor Upregulation Correlates with Improved Outcome in Children with Severe Traumatic Brain Injury. Journal of Neurotrauma, 2008, 25, 225-234.	3.4	114
187	Towards Non Invasive Nerve Growth Factor Therapies for Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 15, 255-283.	2.6	87
188	Nerve Growth Factor and Doublecortin Expression Correlates With Improved Outcome in Children With Severe Traumatic Brain Injury. Journal of Trauma, 2008, 65, 80-85.	2.3	40
189	è„³ã«ãŠã‘ã‚‹ç¥žçµŒæ„Ÿå›žè·¯ãƒ¢. Kagaku To Seibutsu, 2008, 46, 24-31.	0.0	0
190	Polymer-Based Drug Delivery Devices for Neurological Disorders. CNS and Neurological Disorders - Drug Targets, 2009, 8, 205-221.	1.4	23
191	Prothymosin Î± and cell death mode switch, a novel target for the prevention of cerebral ischemia-induced damage. , 2009, 123, 323-333.		37
192	Delivery of peptide and protein drugs over the bloodâ€“brain barrier. Progress in Neurobiology, 2009, 87, 212-251.	5.7	245
193	Alzheimer's disease: clinical trials and drug development. Lancet Neurology, The, 2010, 9, 702-716.	10.2	1,033
194	Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimerâ€™s disease and mild cognitive impairment. Experimental Gerontology, 2010, 45, 41-46.	2.8	57
195	Monocytes deliver bioactive nerve growth factor through a brain capillary endothelial cell-monolayer in vitro and counteract degeneration of cholinergic neurons. Brain Research, 2010, 1312, 108-119.	2.2	28
196	Viral vectors for neurotrophic factor delivery: A gene therapy approach for neurodegenerative diseases of the CNS. Pharmacological Research, 2010, 61, 14-26.	7.1	116
197	The legacy of nanotechnology: Revolution and prospects in neurosurgery. International Journal of Surgery, 2011, 9, 608-614.	2.7	37
198	Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochemical Pharmacology, 2011, 82, 931-942.	4.4	172
199	The Neurotrophins and Their Role in Alzheimers Disease. Current Neuropharmacology, 2011, 9, 559-573.	2.9	130

#	Article	IF	Citations
200	Neuroprotection in Alzheimerâ€™s Disease. , 2011, , 337-367.		0
201	Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2012, 33, 18-28.	1.5	123
202	Nerve growth factor: from the early discoveries to the potential clinical use. Journal of Translational Medicine, 2012, 10, 239.	4.4	352
203	Neurotrophic Factors and Neurodegenerative Diseases. International Review of Neurobiology, 2012, 102, 207-247.	2.0	26
204	A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines. Scientific World Journal, The, 2012, 2012, 1-15.	2.1	626
205	New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. British Journal of Clinical Pharmacology, 2012, 73, 504-517.	2.4	253
206	Nerve growth factor: basic studies and possible therapeutic applications. Growth Factors, 2013, 31, 115-122.	1.7	72
208	GDNF, NGF and BDNF as therapeutic options for neurodegeneration. , 2013, 138, 155-175.		624
209	Nerve Growth Factor-Mediated Regulation of Low Density Lipoprotein Receptor-Related Protein Promoter Activation. Cellular and Molecular Neurobiology, 2013, 33, 269-282.	3.3	5
210	Precautionary effects of RedLiriope platyphyllaon NGF secretion and AÎ²42 deposition under the preclinical stage of Alzheimer's disease in Tg2576 mice. Laboratory Animal Research, 2013, 29, 212.	2.5	6
211	Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair. CNS and Neurological Disorders - Drug Targets, 2014, 12, 1242-1256.	1.4	54
212	Nicotinic Acetylcholine Receptors in Alzheimerâ€™s and Parkinsonâ€™s Disease. , 2014, , 383-415.		0
213	Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases. International Journal of Molecular Sciences, 2014, 15, 1719-1745.	4.1	72
214	Targeting Brain Î±7 Nicotinic Acetylcholine Receptors in Alzheimerâ€™s Disease: Rationale and Current Status. CNS Drugs, 2014, 28, 975-987.	5.9	48
215	Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1316-1328.	0.8	50
216	Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor. Journal of Drug Targeting, 2015, 23, 865-887.	4.4	63
217	Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimerâ€™s disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimer's Research and Therapy, 2016, 8, 30.	6.2	110
218	Short and efficient synthetic route to lembehyne B possessing neuritogenic activity. Russian Journal of Organic Chemistry, 2016, 52, 1844-1846.	0.8	5

#	Article	IF	Citations
219	Total Synthesis of (â˜')-L-755,807: Establishment of Relative and Absolute Configurations. Organic Letters, 2016, 18, 1920-1923.	4.6	15
220	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. Seminars in Nuclear Medicine, 2016, 46, 57-87.	4.6	16
221	Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: Where have we been and what have we learned?. Neurobiology of Disease, 2017, 97, 156-168.	4.4	71
222	Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimerâ€™s disease. Pharmacological Research, 2017, 120, 68-87.	7.1	67
224	Neurotrophin Signaling and Stem Cellsâ€"Implications for Neurodegenerative Diseases and Stem Cell Therapy. Molecular Neurobiology, 2017, 54, 7401-7459.	4.0	49
225	Pumping the Brakes: Neurotrophic Factors for the Prevention of Cognitive Impairment and Dementia after Traumatic Brain Injury. Journal of Neurotrauma, 2017, 34, 971-986.	3.4	15
226	Receptor Targets in Alzheimerâ€™s Disease Drug Discovery. , 2017, , 83-107.		8
227	Targeting Alzheimer's disease with gene and cell therapies. Journal of Internal Medicine, 2018, 284, 2-36.	6.0	42
228	Nerve Growth Factor: Early Studies and Recent Clinical Trials. Current Neuropharmacology, 2018, 16, 1455-1465.	2.9	127
229	REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMERâ€™S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCH. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-14.	2.7	135
230	Cerebrospinal fluid from Alzheimer patients affects cell-mediated nerve growth factor production and cell survival in vitro. Experimental Cell Research, 2018, 371, 175-184.	2.6	11
231	Development and optimization of a novel automated loop method for production of [11C]nicotine. Applied Radiation and Isotopes, 2018, 140, 76-82.	1.5	3
232	Innovative Therapy for Alzheimerâ€™s Disease-With Focus on Biodelivery of NGF. Frontiers in Neuroscience, 2019, 13, 38.	2.8	103
233	The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery. Advances in Experimental Medicine and Biology, 2021, 1331, 31-48.	1.6	2
234	Topical delivery of nerve growth factor for treatment of ocular and brain disorders. Neural Regeneration Research, 2021, 16, 1740.	3.0	18
235	A Review of Techniques for Biodelivery of Nerve Growth Factor (NGF) to the Brain in Relation to Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2021, 1331, 167-191.	1.6	10
236	Nerve Growth Factor Biodelivery: A Limiting Step in Moving Toward Extensive Clinical Application?. Frontiers in Neuroscience, 2021, 15, 695592.	2.8	17
237	Nerve Growth Factor-Based Therapy in Alzheimerâ€™s Disease and Age-Related Macular Degeneration. Frontiers in Neuroscience, 2021, 15, 735928.	2.8	15

#	Article	IF	Citations
238	Gene and cell therapy for the nucleus basalis of Meynert with NGF in Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 219-229.	1.8	1
239	The Problems of Delivering Neuroactive Molecules to the CNS. Novartis Foundation Symposium, 1996, 196, 211-239.	1.1	10
240	Current Neurotransmitter Strategies in AD Drug Development. Advances in Behavioral Biology, 1998, , 851-859.	0.2	1
241	Use of PET Technique to Monitor Effect of Drugs in Alzheimer Disease Treatment. , 1994, , 405-412.		4
242	Therapeutic Strategies in Alzheimerâ€™s Disease. , 1994, , 485-492.		1
243	Gene Therapies for Parkinsonâ€™s Disease. , 1998, , 377-395.		8
244	GDNF delivery for Parkinsonâ€™s disease. , 2007, 97, 135-154.		60
245	Noninvasive Exploration of Nicotinic Acetylcholine Receptors In Vivo. Handbook of Experimental Pharmacology, 2000, , 539-561.	1.8	2
246	Nerve Growth Factor Treatment for Alzheimerâ€™s Disease: The Experience of the First Attempt at Intracerebral Neurotrophic Factor Therapy. Handbook of Experimental Pharmacology, 1999, , 175-187.	1.8	5
247	Ex Vivo Gene Therapy in the Central Nervous System. Handbook of Experimental Pharmacology, 2002, , 301-333.	1.8	1
248	Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. Journal of Neural Transmission Supplementum, 1998, 53, 289-298.	0.5	56
249	Peripheral Administration of Nerve Growth Factor Conjugated to an Anti-transferrin Receptor Antibody Increases Cholinergic Neuron Survival in Intraocular Forebrain Transplants. Methods in Neurosciences, 1994, , 71-92.	0.5	3
250	Neurotrophic Factors, Gene Therapy, and Alzheimer's Disease. , 1999, , 505-XIII.		2
251	Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease.. Journal of Clinical Investigation, 1997, 100, 2333-2340.	8.2	306
252	Wine and migraine. , 2002, , 274-284.		2
253	Neural Growth Factor Stimulates Proliferation of Spinal Cord Derived-Neural Precursor/Stem Cells. Journal of Korean Neurosurgical Society, 2016, 59, 437.	1.2	5
254	Effcacy and safety of nerve growth factor for the treatment of neurological diseases: a meta-analysis of 64 randomized controlled trials involving 6,297 patients. Neural Regeneration Research, 2015, 10, 819.	3.0	22
255	Cerebrospinal fluid and blood biomarkers in Alzheimerâ€™s disease. World Journal of Psychiatry, 2011, 1, 8.	2.7	34

#	Article	IF	Citations
257	Neurotrophic factors and synaptic plasticity in the adult hippocampus. , 2002, , 61-77.		1
258	Development of Neurotrophic Factor Therapy for Alzheimer's Disease. Novartis Foundation Symposium, 1996, 196, 54-69.	1.1	6
259	Somatic Gene Therapy for Nervous System Disease. Novartis Foundation Symposium, 1996, 196, 85-97.	1.1	2
260	Intermittent vs Continuous Administration of Nerve Growth Factor to Injured Medial Septal Cholinergic Neurons in Rat Basal Forebrain. Neuroscience and Medicine, 2014, 05, 109-118.	0.2	0
261	Reparative Strategies in the Brain: Treatment Strategies Based on Trophic Factors and Cell Transfer Techniques. , 1993, 58, 3-7.		5
262	Neurotrophins in the Adult Brain: Effects on Hippocampal Cholinergic Function Following Deafferentation, and Regulation of Their Expression by Pharmacological Agents and Lesions. , 1993, , 241-253.		0
263	Target-Specific Outgrowth from Grafted Dopaminergic Neurons. , 1994, , 567-579.		0
264	NGF and Alzheimerâ€™s disease: a model for trophic factor therapy in neurodegeneration. Key Topics in Brain Research, 1994, , 115-130.	0.2	0
265	Localization of Neurotrophins and Their Receptors at the mRNA and Protein Level. , 1994, , 151-165.		0
266	Contribution of Cell Culture to Understanding Neuronal Aging and Degeneration. , 1994, , 29-34.		0
267	Non-Cholinergic Therapies of Dementia. , 1994, , 493-509.		0
268	The Pharmacology of Neurotrophic Factors. , 1995, , 241-254.		4
269	Future Directions and Clinical Prospects of Neurotrophic Factor Research. , 1995, , 441-452.		0
270	Positron Emission Tomography (PET) Studies with Ligands for Cholinergic Receptors in the Human Brain. Advances in Behavioral Biology, 1995, , 245-249.	0.2	1
271	Therapeutic Use of Neurotrophic Factors. , 1995, , 379-390.		0
272	The regulation of nerve growth factor synthesis and delivery to peripheral neurons. , 1996, , 171-202.		0
273	Design of Membrane-Based Bioartificial Organs. , 1996, , 223-236.		1
274	Treatment of Alzheimer's Disease. , 1996, , .		0

#	Article	IF	Citations
275	Treatment strategies for neurodegenerative diseases based on trophic factors and cell transplantation techniques. , 1997, 49, 1-10.		29
276	Therapy of Alzheimerâ€™s Dementia. , 1998, , 179-196.		0
277	Treatment of Central Nervous System Diseases with Polymer-Encapsulated Xenogeneic Cells. , 1998, , 253-286.		0
278	Geriatric Neurology and Psychiatry. Handbook of Experimental Pharmacology, 1999, , 473-503.	1.8	0
279	Neue BehandlungsansÃtze bei der Alzheimer-Demenz. , 1999, , 753-770.		0
280	Trophic Factors in Experimental Models of Adult Central Nervous System Injury. Cerebral Cortex, 1999, , 129-173.	0.6	0
281	Tissue Engineering in the Nervous System. The Electrical Engineering Handbook, 1999, , .	0.2	6
282	Proceso inflamatorio en la enfermedad de Alzheimer. Papel de las citoquinas. , 2014, , 121-156.		0
283	EXPRESSION OF THE NERVE GROWTH FACTOR DURING EMBRYONIC GROWTH PERIOD OF JAPANESE QUAIL (COTURNIX COTURNIX JAPONICA). Mehmet Akif Ersoy Ãœniversitesi Veteriner FakÃ¼ltesi Dergisi, 2016, 1, 11-11.	0.3	0
285	Neuroprotection in experimental stroke with targeted neurotrophins. Neurotherapeutics, 2005, 2, 120-128.	4.4	0
286	Therapeutic potential of neurotrophic factors in Alzheimerâ€™s Disease. Molecular Biology Reports, 2022, 49, 2345-2357.	2.3	18
287	Intranasal Delivery of Nerve Growth Factor in Neurodegenerative Diseases and Neurotrauma. Frontiers in Pharmacology, 2021, 12, 754502.	3.5	10
288	Reimagining cholinergic therapy for Alzheimerâ€™s disease. Brain, 2022, 145, 2250-2275.	7.6	50
291	Fast Alpha Activity in EEG of Patients With Alzheimerâ€™s Disease Is Paralleled by Changes in Cognition and Cholinergic Markers During Encapsulated Cell Biodelivery of Nerve Growth Factor. Frontiers in Aging Neuroscience, 2022, 14, 756687.	3.4	3
293	An Antibody-Avidin Fusion Protein Specific for the Transferrin Receptor Serves as a Delivery Vehicle for Effective Brain Targeting: Initial Applications in Anti-HIV Antisense Drug Delivery to the Brain. Journal of Immunology, 1999, 163, 4421-4426.	0.8	76
294	Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimerâ€™s disease. Chemical Engineering Journal, 2023, 466, 143152.	12.7	4
295	THERAPY OPTIONS IN ALZHEIMER'S DISEASE. International Journal of Clinical Practice, 1994, 48, 327-330.	1.7	7
296	Aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model. Neuroscience Letters, 2023, 812, 137410.	2.1	2